Creabilis hires chief medical officer

Dr David Roblin joins the firm after holding leading roles at Pfizer and Bayer

Creabilis, a clinical stage European biotechnology company focused on dermatology, inflammation and pain, has appointed David Roblin as chief medical officer.

Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years. He has held leadership roles at Pfizer and Bayer across a range of therapy areas in research, development and commercial roles.

At Pfizer, Roblin was most recently senior vice president, head of research and site head for European r&d. Before this, he was head of anti-infectives at Bayer Medical Affairs.

In addition Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a US$2bn public-private partnership with the European Commission.

You may also like

Finance

Creabilis establishes UK operation

Location in Kent broadens the county’s links with the pharma industry
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Sustainability

Solvent recyclers improve HPLC system sustainability

A leading pharmaceutical company has purchased 17 SPR-200 solvent recycler units from Biotech Fluidics improving sustainable use of solvents by HPLC systems in their analytical laboratories
Pharmaceutical

Polpharma Biologics announces US launch of Tyruko, the first FDA-approved natalizumab biosimilar for MS

Tyruko is now available to US patients with multiple sclerosis and Crohn’s disease, expanding access to a more affordable biologic option
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Subscribe now